The Utility and Potential of Comprehensive Genomic Profiling

2020년 11월 2일

In this educational video, Dr. David Eberhard, Senior Medical Director in Oncology at Illumina, explains what comprehensive genomic profiling (CGP) is and how it provides cancer patients and oncologists with a powerful testing approach to help identify biomarkers for therapy selection and eligibility for clinical trials. In addition, he discusses how CGP brings many benefits to a pathology lab, and is the most effective approach for biomarker profiling in a world where new cancer therapy biomarkers are being developed at a rapid pace. Learn more about the future in Oncology: https://emea.illumina.com/areas-of-interest/cancer/future-of-ngs-in-oncology.html Subscribe to the Illumina video channel http://www.youtube.com/subscription_center?add_user=IlluminaInc A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. *Data calculations on file. Illumina, Inc., 2015. View customer spotlight videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79 View Illumina webinars https://www.youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ View Illumina product videos https://www.youtube.com/playlist?list=PLKRu7cmBQlaj6YuZmkfxZcT9twqDgP2Xd View Illumina support videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM

다음을 통해 기사 공유하기: